financetom
Business
financetom
/
Business
/
TPG Q3 Loss Narrows, Revenue Increases; Quarterly Dividend Lowered
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TPG Q3 Loss Narrows, Revenue Increases; Quarterly Dividend Lowered
Nov 4, 2024 12:01 PM

08:52 AM EST, 11/04/2024 (MT Newswires) -- TPG (TPG) reported a Q3 loss Monday of $0.08 per diluted share, narrowing from a loss of $0.09 a year earlier.

A single analyst polled by Capital IQ expected earnings of $0.48.

Revenue for the quarter ended Sept. 30 was $855.4 million, up from $160.4 million a year earlier.

Analysts surveyed by Capital IQ expected $450.1 million.

TPG also lowered its quarterly dividend to $0.38 per share, payable Dec. 2 to shareholders of record as of Nov. 14.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
--MarketWise Keeps Quarterly Cash Dividend at $0.01 Per Share, Payable April 25 to Shareholders on March 15
--MarketWise Keeps Quarterly Cash Dividend at $0.01 Per Share, Payable April 25 to Shareholders on March 15
Mar 5, 2024
03:19 PM EST, 03/05/2024 (MT Newswires) -- Price: 1.75, Change: -0.06, Percent Change: -3.31 ...
Chile's Cencosud posts Q4 profit down 42%
Chile's Cencosud posts Q4 profit down 42%
Mar 5, 2024
March 5 (Reuters) - Chile's Cencosud, one of Latin America's largest retailers, on Tuesday reported a 42% fall in fourth-quarter net profit, landing at 83.3 billion pesos ($94 million), while revenues shrunk 16% to 3.30 trillion pesos. ...
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
Why Are Dialysis Provider Stocks Trading Higher On Tuesday?
Mar 5, 2024
Tuesday, Novo Nordisk A/S ( NVO ) released the headline results from the kidney outcomes trial, FLOW. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression as well as cardiovascular and kidney death of 24% for people treated with semaglutide 1.0 mg compared to placebo.  Stocks of kidney dialysis-focused DaVita Inc , Fresenius Medical Care AG , and Baxter International...
Market Chatter: Citigroup Chief Executive Forecasts Surge in Investment Banking Fees Amid Decline in Markets Revenue
Market Chatter: Citigroup Chief Executive Forecasts Surge in Investment Banking Fees Amid Decline in Markets Revenue
Mar 5, 2024
03:26 PM EST, 03/05/2024 (MT Newswires) -- Citigroup ( C ) foresees a mid-teens percentage increase in investment banking fees during the first quarter compared with the fourth quarter of 2023, Reuters reported Tuesday, citing Chief Executive Jane Fraser at a conference in New York. Fraser told investors that markets revenue is expected to decrease by 8% to 12% in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved